Intellectus Partners LLC Grows Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Intellectus Partners LLC grew its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 9.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 55,650 shares of the company’s stock after buying an additional 4,900 shares during the period. Intellectus Partners LLC owned approximately 0.06% of Intellia Therapeutics worth $1,697,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. ARK Investment Management LLC grew its stake in Intellia Therapeutics by 14.7% in the 4th quarter. ARK Investment Management LLC now owns 11,412,449 shares of the company’s stock worth $347,966,000 after buying an additional 1,463,820 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. grew its stake in Intellia Therapeutics by 3.7% in the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 3,520,295 shares of the company’s stock worth $111,312,000 after buying an additional 125,639 shares in the last quarter. Wellington Management Group LLP grew its stake in Intellia Therapeutics by 1.4% in the 3rd quarter. Wellington Management Group LLP now owns 2,651,994 shares of the company’s stock worth $83,856,000 after buying an additional 36,630 shares in the last quarter. Federated Hermes Inc. grew its stake in Intellia Therapeutics by 13.8% in the 4th quarter. Federated Hermes Inc. now owns 2,016,300 shares of the company’s stock worth $61,477,000 after buying an additional 244,722 shares in the last quarter. Finally, Chevy Chase Trust Holdings LLC grew its stake in Intellia Therapeutics by 3.0% in the 3rd quarter. Chevy Chase Trust Holdings LLC now owns 1,002,955 shares of the company’s stock worth $31,713,000 after buying an additional 29,412 shares in the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Analysts Set New Price Targets

NTLA has been the subject of a number of recent research reports. Canaccord Genuity Group boosted their price objective on shares of Intellia Therapeutics from $72.00 to $73.00 and gave the stock a “buy” rating in a report on Friday, February 23rd. The Goldman Sachs Group lowered shares of Intellia Therapeutics from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $136.00 to $32.00 in a report on Friday, February 23rd. Wolfe Research initiated coverage on shares of Intellia Therapeutics in a report on Thursday, February 15th. They issued a “peer perform” rating for the company. Finally, Wedbush restated a “neutral” rating and issued a $29.00 price objective on shares of Intellia Therapeutics in a report on Tuesday, April 23rd. One analyst has rated the stock with a sell rating, four have assigned a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $67.00.

Intellia Therapeutics Stock Up 3.7 %

Intellia Therapeutics stock traded up $0.74 during mid-day trading on Friday, reaching $20.76. 1,025,682 shares of the company traded hands, compared to its average volume of 1,154,036. The firm’s 50 day moving average price is $26.51 and its 200 day moving average price is $27.54. Intellia Therapeutics, Inc. has a 52-week low of $19.37 and a 52-week high of $47.48.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings data on Thursday, February 22nd. The company reported ($1.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.01. The business had revenue of ($1.92) million for the quarter, compared to the consensus estimate of $15.10 million. Intellia Therapeutics had a negative net margin of 893.34% and a negative return on equity of 43.91%. During the same period in the previous year, the firm earned ($1.40) EPS. Research analysts anticipate that Intellia Therapeutics, Inc. will post -5.57 EPS for the current year.

Insider Transactions at Intellia Therapeutics

In other news, EVP James Basta sold 2,297 shares of the company’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $32.99, for a total value of $75,778.03. Following the sale, the executive vice president now directly owns 81,571 shares of the company’s stock, valued at approximately $2,691,027.29. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 3.00% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.